Evidence map›Paper›PMID 25898318›Full record

ArticlePloS one2015

Alarmin function of galectin-9 in murine respiratory tularemia.

Anthony L Steichen, Tanner J Simonson, Sharon L Salmon, Dennis W Metzger, Bibhuti B Mishra, Jyotika Sharma

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Galectin-9Aging cell · 2026
    Article
  3. Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Protective role of Galectin-7 for skin barrier impairment in atopic dermatitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. The emerging role of galectins in high-fatality cancers.Cellular and molecular life sciences : CMLS · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anthony L SteichenDepartment of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States of America.
Tanner J SimonsonDepartment of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States of America.
Sharon L SalmonCenter for Immunology and Microbial Disease, Albany Medical College, Albany, New York, United States of America.
Dennis W MetzgerCenter for Immunology and Microbial Disease, Albany Medical College, Albany, New York, United States of America.
Bibhuti B MishraDepartment of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States of America.
Jyotika SharmaDepartment of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, United States of America.
University of North Dakota · USAlbany Medical Center Hospital · US

Funding

TLR2/NLR Signal Regulation of Protective Immunity to F. TularensisP01AI056320 · NIAID · ALBANY MEDICAL COLLEGE · PI METZGER, DENNIS W · 2003 to 2016
$22.9M
Pilot Projects CoreP30GM103329 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI GEIGER, JONATHAN DAVID · 2012 to 2016
$5.1M
Mechanism of sepsis development in pulmonary bacterial infectionR21AI101644 · NIAID · UNIVERSITY OF NORTH DAKOTA · PI SHARMA, JYOTIKA · 2012 to 2013
$387k
NIAID NIH HHS 1R21AI101644-01NIAID NIH HHS P01 AI056320NIAID NIH HHS P01AI56320NIAID NIH HHS R21 AI101644NIGMS NIH HHS P30 GM103329
6 · The paper itself

Abstract

Sepsis is a complex immune disorder that is characterized by systemic hyperinflammation. Alarmins, which are multifunctional endogenous factors, have been implicated in exacerbation of inflammation in many immune disorders including sepsis. Here we show that Galectin-9, a host endogenous β-galactoside binding lectin, functions as an alarmin capable of mediating inflammatory response during sepsis resulting from pulmonary infection with Francisella novicida, a Gram negative bacterial pathogen. Our results show that this galectin is upregulated and is likely released during tissue damage in the lungs of F. novicida infected septic mice. In vitro, purified recombinant galectin-9 exacerbated F. novicida-induced production of the inflammatory mediators by macrophages and neutrophils. Concomitantly, Galectin-9 deficient (Gal-9-/-) mice exhibited improved lung pathology, reduced cell death and reduced leukocyte infiltration, particularly neutrophils, in their lungs. This positively correlated with overall improved survival of F. novicida infected Gal-9-/- mice as compared to their wild-type counterparts. Collectively, these findings suggest that galectin-9 functions as a novel alarmin by augmenting the inflammatory response in sepsis development during pulmonary F. novicida infection.

Indexed as

AlarminsAnimalsBronchopneumoniaFemaleFrancisellaGalectinsInflammation MediatorsLungMice, Inbred C57BLMice, KnockoutNeutrophilsPneumonia, BacterialTularemiaAlarminsgalectin 9, mouseGalectinsInflammation Mediators

Identifiers

PMID25898318
PMCPMC4405590
OpenAlexW2004350933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.